Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
109,628,845
-
Total 13F shares
-
54,460,975
-
Share change
-
+3,100,539
-
Total reported value
-
$1,174,838,680
-
Put/Call ratio
-
32%
-
Price per share
-
$21.57
-
Number of holders
-
152
-
Value change
-
+$53,634,951
-
Number of buys
-
95
-
Number of sells
-
64
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) as of Q2 2023
As of 30 Jun 2023,
Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) was held by
152 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,460,975 shares.
The largest 10 holders included
VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, BlackRock Inc., VIKING GLOBAL INVESTORS LP, Boxer Capital, LLC, MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., Rock Springs Capital Management LP, and FEDERATED HERMES, INC..
This page lists
153
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.